The FDA Modernization Act 2.0 has shifted from animal testing to New Approach Methodologies (NAMs) for preclinical drug development. Three-dimensional (3D) bioprinting has emerged as a premier NAM, ...
At TU Wien, researchers are developing three-dimensional (3D) printing techniques that can be used to create living biological tissue—for example, to study skin diseases. Roughly one-quarter of Europe ...
Recent advances in the field of biomaterials show promise in developing pre-clinical models that could elucidate new and innovative treatments for cancer. Both cellular and acellular components can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results